Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 5Recurrence 2Neoplasm Metastasis 2Waldenstrom Macroglobulinemia 1Solid Tumor 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Tumors 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Rituximab 30ibrutinib 26Bendamustine Hydrochloride 18Cyclophosphamide 17acalabrutinib 14fludarabine 13Lenalidomide 11zanubrutinib 10venetoclax 9Vincristine 7Bortezomib 7pirtobrutinib 5brexucabtagene autoleucel 5Prednisone 5Doxorubicin 5temsirolimus 4parsaclisib 4aflibercept 4Gemcitabine 4ublituximab 3orelabrutinib 3loncastuximab tesirine 3idelalisib 3ibritumomab tiuxetan 3Sensitivity and Specificity 3Antigens, CD19 3tositumomab I-131 2tazemetostat 2pembrolizumab 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Mantle-Cell × WW Domain-Containing Oxidoreductase × Clear all
NCT00063713 2008-02-11

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
152 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡